Prof. Dr. Dongfeng Zeng | hematology | Excellence in Research

Prof. Dr.  Dongfeng Zeng,  Daping Hospital, Third Military Medical University (Army Medical University), China.

Dr. Zeng Dongfeng’s career is a testament to his dedication to hematology, patient care, and research. From his early academic pursuits to his professional achievements, he has consistently demonstrated excellence in the field. His research contributions in hematopoietic stem cell transplantation, G-CSF preconditioning, and immunotherapy for blood disorders have paved the way for innovative treatments. His recognition as a distinguished scholar and his mentorship of aspiring medical professionals further cement his impact on the medical community.

Profile

Scopus

🎓 Early Academic Pursuits

From the very beginning of his academic journey, Dr. Zeng Dongfeng exhibited an unwavering dedication to the field of medicine. His passion for understanding the complexities of hematology led him to earn a Doctor of Medicine degree, where he developed a deep-rooted expertise in treating blood disorders. His educational foundation was instrumental in shaping his approach to clinical research, patient care, and medical innovations. With rigorous training and an insatiable curiosity, Dr. Zeng embarked on a path that would position him as a key figure in hematological advancements.

🏋️‍♂️ Professional Endeavors

Dr. Zeng’s career commenced at Xinqiao Hospital, where he served as an attending physician and lecturer in the Department of Hematology. His expertise and leadership skills quickly became evident, leading him to take on significant roles in various prestigious institutions. His tenure at the Tibet Military Region General Hospital provided him with a unique perspective on treating patients in diverse and challenging environments. Further strengthening his credentials, he pursued postdoctoral research at the Institute of Combined Injury at the Third Military Medical University. His career continued to flourish as he assumed responsibilities as an associate chief physician, associate professor, and deputy director at the Army Specialty Medical Center.

🔬 Contributions and Research Focus

Throughout his career, Dr. Zeng has focused on cutting-edge research aimed at revolutionizing the treatment of hematological disorders. His studies on hematopoietic stem cell transplantation for pediatric hematologic malignancies laid the groundwork for improved therapeutic strategies. His extensive research on G-CSF pre-stimulation and preconditioning regimens for MRC-AML has contributed to advancements in transplantation techniques. Additionally, his work on sequential low-dose decitabine therapy for elderly MDS patients has provided new hope for those struggling with myelodysplastic syndromes. Dr. Zeng’s involvement in monitoring the effects of sintilimab injection and evaluating novel therapies such as Ociperlimab in combination with chemotherapy for metastatic non-small cell lung cancer underscores his commitment to pioneering transformative treatments in the medical field.

🏆 Accolades and Recognition

Dr. Zeng’s expertise and contributions have earned him widespread recognition in the medical community. His role as a visiting scholar at the MD Anderson Cancer Center in the United States provided him with international exposure and the opportunity to collaborate with global leaders in oncology and hematology. His reputation as a dedicated clinician, researcher, and mentor has solidified his status as a respected figure in his field. Through his continuous efforts in advancing hematological research, he has become a beacon of excellence, inspiring future generations of medical professionals.

📚 Impact and Influence

Beyond his clinical and research contributions, Dr. Zeng has profoundly impacted the medical field through his mentorship and guidance. By leading innovative studies, he has not only shaped the direction of hematology but also influenced young researchers and physicians who aspire to follow in his footsteps. His work has played a pivotal role in improving patient outcomes and developing new standards of care, proving that his influence extends far beyond the walls of his medical institution. His collaborations with international researchers have further expanded the scope of hematological treatments and their applicability in real-world scenarios.

🌟 Legacy and Future Contributions

As a visionary in hematology, Dr. Zeng Dongfeng continues to push the boundaries of medical research and patient care. His ongoing studies on hepatitis B reactivation prevention in CD20-positive B-cell lymphoma patients and immunotherapy applications in metastatic lung cancer demonstrate his relentless pursuit of medical breakthroughs. His legacy is not only built on the achievements of the past but also on the promise of future innovations. With each clinical trial and research endeavor, Dr. Zeng is shaping the future of hematology, leaving behind a lasting impact that will benefit generations to come.

Publication

• Title: Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
  Author: F. Meng, M. Xiang, Y. Liu, D. Zeng
  Year: 2024

 

• Title: IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
  Author: H. Xie, J. Zhang, R. Luo, X. Li, D. Zeng
  Year: 2024

 

• Title: Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma
  Author: J. Feng, Y. Fei, M. Gao, X. Wang, H. Zhang
  Year: 2024

 

• Title: Supplementing Glucose Intake Reverses the Inflammation Induced by a High-Fat Diet by Increasing the Expression of Siglec-E Ligands on Erythrocytes
  Author: H. Liu, J. Li, N. Wu, D. Zeng, Y. Jia
  Year: 2024

 

• Title: Quadruple stem cells transplantation of haploidentical bone marrow and PBSCs supporting by third-party umbilical cord blood and MSCs achieved excellent outcomes
  Author: C. Luo, X. Li, B. Yan, X. Wu, S. Xu
  Year: 2024

 

• Title: Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE
  Author: D. Zeng, Y. Fang, Y. Fei, D. Zou, Q. Cai
  Year: 2023

 

• Title: ARHGAP4 promotes leukemogenesis in acute myeloid leukemia by inhibiting DRAM1 signaling
  Author: Y. Qi, M. Hu, C. Han, J. Wang, D. Zeng
  Year: 2023

 

💡 Conclusion

Dr. Zeng Dongfeng’s journey in hematology is a reflection of his passion, perseverance, and commitment to advancing medical science. His groundbreaking research and clinical expertise have significantly improved treatment options for patients with hematological disorders. As he continues his pursuit of scientific discoveries and patient-centered innovations, his contributions will undoubtedly shape the future of hematology and inspire future generations of medical professionals worldwide. His legacy stands as a guiding light for those who seek to make a meaningful difference in the field of medicine.